BPH-1358

BPH-1358 (NSC50460) is a potent human farnesyl diphosphate synthase (FPPS) and undecaprenyl diphosphate synthase (UPPS) inhibitor with IC50s of 1.8 μM and 110 nM, respectively, and is active against S. aureus in vitro (MIC ~250 ng/mL) [1][2].

5352-53-4

NSC50460

12352005

Bacterial

Reference compound

Anti-infection

COVID-19-immunoregulation

Cancer; Infection

https://www.medchemexpress.com/bph-1358.html

99.12

DMSO : 4.04 mg/mL (ultrasonic; warming; heat to 60°C)

O=C(C1=CC=C(C2=CC=C(C(NC3=CC=CC(C4=NCCN4)=C3)=O)C=C2)C=C1)NC5=CC=CC(C6=NCCN6)=C5.[H]Cl.[H]Cl

C32H30Cl2N6O2

601.53

[1] Liu YL, et al. Farnesyl diphosphate synthase inhibitors with unique ligand-binding geometries. ACS Med Chem Lett. 2015 Jan 29;6 (3) :349-54.|[2]Zhu W, et al. Antibacterial drug leads: DNA and enzyme multitargeting. J Med Chem. 2015 Feb 12;58 (3) :1215-27.

Room Temperature

4°C (Powder, sealed storage, away from moisture and light)

http://file.medchemexpress.com/batch_PDF/HY-118946/BPH-1358-SDS-MedChemExpress.pdf

Reference compound1

No Development Reported